
Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
SYDNEY, Jan. 30, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in […]